



Sarah Barkow, Ph.D.


Acting Director, MQGPS Office of Manufacturing Quality Center for Drug Evaluation and Research Office of Compliance September 5, 2018 Baltimore, MD


**GRx + Biosims 2018: Association for Accessible Medicines** 

DISCLAIMER: The views and opinions expressed in this presentation are those of the authors and do not necessarily represent official policy or position of the Food and Drug Administration



#### **CDER Office of Compliance**





#### **Responsibility Throughout Lifecycle**

**Outside the Normal Lifecycle** 

#### **ODSIR & OUDLC**


- Internet Pharmacies and Counterfeit Drugs
- Marketed Unapproved Drugs, OTC Drug Compliance, Health Fraud, and Compounding

**FDA** 



## **DI Warning Letters by Year**

OMQ WLs with DI lapses



- About 40% of OMQ's warning letters include data integrity lapses.
- These letters went to manufacturers around the world.

DI Other

\*Through July 31, 2018 Excludes compounding-related actions



#### Data Integrity

- Data integrity evidence that data are complete, consistent, and accurate.
- Applies to CGMP via the FD&C Act, CFR 210, 211, 212, ICH Q7 and other guidance.
- <u>Draft FDA guidance document</u>, *Data Integrity and Compliance with CGMP*, published April 2016, to clarify the role of data integrity in CGMP for drugs.

Link: <u>https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm495891.pdf</u>

#### **Data Integrity**

- CGMP is the minimum requirement.
- Data integrity underpins CGMP.
- Lapses obscure other problems.

## DI problems you can see are the tip of the iceberg.



FD/

#### Data Integrity Case Study: Laboratory Data

- Audit trail review showed results deleted routinely
- Audit trails showed tests being repeated without justification or investigation
- Lab instruments weren't networked or otherwise backed-up
- Employees shared usernames and passwords
- [] stated that "when chromatograms don't look right, they are deleted" followed by "retesting."





#### **Audit Trail**

		188	10110		
	PARTICIA-	AND THE REAL PROPERTY AND ADDRESS OF ADDRESS OF ADDRESS ADDRES	MARCH & CO.	States in states	
	PARTICIPACION	And the second damage and agreened of an include a second	manage and so see	And Inches	
	COLUMN A	BUT THE REAL POST OF THE PARTY	married in the data		
	THE R. P.	NOT THE REAL OF THE REAL PROPERTY AND AND ADDRESS OF A DESCRIPTION OF A DE	Internet and in the local		
	THE R. P.	N. 1 THERE STATISTICS IN THE COLUMN AS A REAL PROPERTY OF A REAL PROPE			
	and other as	a second an interested in here			
-	are-search-	a second data and a second of the second			
			REAL PROPERTY AND ADDRESS		States and states and
-	Contraction -	a de and dauto annend in an inn	20122-02.00	(148	total protocolog
-	A & C & C & C & C & C & C & C & C & C &	Rectofferentied in			THE OWNER OF
-	And the owner.	RADING RUDBERG (1)	manual is in order		
-	Canada .				
	Cardina .		10510 1.4.8.0	10.00 Page	April 14
		A REAL STREET SHOULD BE AN AN AN AND AND AN	and the set of the set	1.11	1000 C. H. 10 F
	A181418-18	and the second se		100.000	
-	A DE LA CHARLES	Reck Barrent of	States of a search	A	
10.0	Cardin .		ABAR AN AM		
10	Lauge-				
20.00	10034		DAMES NO. OFFICE	1000	and the second s
	Lange B.	BUT WERE ANY OF BRIDE BRIDE DURING ST. DOWN MARK			
	Sub-search.	2 - Die die Der Berteinen anderen in	and a read	-	
	CONTRACT.	ALL BREED CONTRACTOR OF THE CONTRACT PROPERTY OF			
		AL DESCRIPTION DESCRIPTION OF ADDRESS ADDRESS			
100	- and the second	** PERMITS			
100	and the second s	A 1 DECEMBER OF COMPANY OF A DECEMBER OF A D		1000 2000	TABLE AVERAGE AND
-	THE R. L.		markets or the party		
100	And and a state of the state of	A DESCRIPTION OF A DESC			
100	TAXABLE PARTY.	A REAL PROPERTY AND ADDRESS OF ADDRESS OF			
	PARTY.	No. of the local division of the second second second second			
-	and designed	> contact descendential or			
100	COLLEGE AND	A DESERVICION DESERVED AND ADDRESS OF A DES			
	Description.	I STREET AND DRIVE STREET, ALL PROPERTY AND ADDRESS OF THE			
		A DECEMBER OF STREET OF STREET STREET,			



#### Question 1

Failing results on an assay, now what?a) Conduct an investigationb) Document the failurec) Just keep testing until something passesd) Delete any failing results

You should document the failure and conduct an Out-of-Specification investigation. The firm opted for c and d.



### Question 2

Reasons to delete CGMP data:

- a) Your hard drive is full
- b) You only need one passing result
- c) They weren't real results in the first place
- d) Oops, it was an accident

The firm claimed the deletions were just solvent injections to get a stable baseline or were to decrease the number of saved chromatograms on the computer.



#### Warning Letter

# "Failure to maintain complete data derived from all laboratory tests conducted to ensure compliance with established specifications and standards.

"Our investigators observed systemic data manipulation across your facility. They documented unexplained deletions of laboratory test results. They discovered that you repeated tests until you obtained acceptable results and that you failed to investigate out-of-specification or otherwise undesirable test results. Your firm relied on these falsified and manipulated test results to support batch release and stability data... "



#### How to Remediate aka DI Remediation Three-Step

Recent FDA warning letters with data integrity citations ask firms to respond by taking these three steps:

- Comprehensive investigation
- Risk assessment
- Remediation and management strategy including corrective action plan



### Contract Manufacturing Case Study: What You See is What You Get

- Products were not tested for microbial contamination or sterility.
- Firm "lost" qualification data.
- Firm routinely did not record (or measure?) weight of samples, test methods, calculations performed.



#### Question(s) 3-5

- 3) If you rely on certificates of analysis, what do you know?
- 4) If you do a paper audit, what do you know?
- 5) If you do a physical audit, what do you know?



#### Warning Letter

Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to assure compliance with established specifications and standards (21 CFR 211.194(a)).

 Your firm was unable to provide complete raw data related to the qualification of your [] water system. You lacked basic information (including missing sanitization data) to assess water system performance. According to your employee, half the data you generated over a year was lost.



#### **FDA Quality Agreements Guidance**

Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Veterinary Medicine (CVM)

November 2016 Pharmaceutical Quality/Manufacturing Standards (CGMP) Quality agreements define expectations and responsibilities in a contract manufacturing arrangement up front.

https://www.fda.gov/downloads/drugs/guidancecomplianceregulato ryinformation/guidances/ucm353925.pdf



# Thank you

Contact: sarah.barkow@fda.hhs.gov